Satake K, Chung Y S, Yokomatsu H, Nakata B, Sawada T, Nishiwaki H, Umeyama K
First Department of Surgery, Osaka City University Medical School, Japan.
Pancreas. 1991 Mar;6(2):234-41. doi: 10.1097/00006676-199103000-00017.
Various tumor markers for detection of small pancreatic cancer less than 4.0 cm of diameter were evaluated and our recent 2 year experience is presented. Even in T1 cancer, 62.5% of the patients (N = 24) had elevated serum CA 19-9 and 56.5% of the patients also had elevated serum SPan-1. However, that of other markers was less than 30% except for CA 50 (60%). In T2 cancer, the highest sensitivity was observed for SPan-1 (79.6%, N = 54) and that of Ca 19-9 (N = 54) was also high (77.7%). That of other markers was less than 50%. The combination assay of CA 19-9 and SPan-1 in T1 cancer increased sensitivity from a single assay of 62.5% and 56.5%, respectively, to 70%. In T2 cancer, the sensitivity of the combination was 97.1%. All of our cases showed positive results using serum SPan-1 and/or CA 19-9 before confirming the diagnosis with imaging procedures. By applying measurements accurately, the test is a very useful adjunct to the diagnosis of small pancreatic cancer and therefore improves its prognosis.
我们评估了多种用于检测直径小于4.0 cm的小胰腺癌的肿瘤标志物，并介绍了我们最近两年的经验。即使在T1期癌症中，62.5%的患者（N = 24）血清CA 19-9升高，56.5%的患者血清SPan-1也升高。然而，除CA 50（60%）外，其他标志物的升高率均低于30%。在T2期癌症中，SPan-1的敏感性最高（79.6%，N = 54），CA 19-9（N = 54）的敏感性也较高（77.7%）。其他标志物的敏感性低于50%。T1期癌症中CA 19-9和SPan-1的联合检测将敏感性从单项检测的62.5%和56.5%分别提高到70%。在T2期癌症中，联合检测的敏感性为97.1%。在通过影像学检查确诊之前，我们所有的病例血清SPan-1和/或CA 19-9检测结果均为阳性。通过准确应用检测手段，该检测对于小胰腺癌的诊断是非常有用的辅助手段，因此改善了其预后。
